These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29760531)

  • 1. The reactivity-driven biochemical mechanism of covalent KRAS
    Hansen R; Peters U; Babbar A; Chen Y; Feng J; Janes MR; Li LS; Ren P; Liu Y; Zarrinkar PP
    Nat Struct Mol Biol; 2018 Jun; 25(6):454-462. PubMed ID: 29760531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proof of concept for poor inhibitor binding and efficient formation of covalent adducts of KRAS
    Khrenova MG; Kulakova AM; Nemukhin AV
    Org Biomol Chem; 2020 Apr; 18(16):3069-3081. PubMed ID: 32101243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.
    Zeng M; Lu J; Li L; Feru F; Quan C; Gero TW; Ficarro SB; Xiong Y; Ambrogio C; Paranal RM; Catalano M; Shao J; Wong KK; Marto JA; Fischer ES; Jänne PA; Scott DA; Westover KD; Gray NS
    Cell Chem Biol; 2017 Aug; 24(8):1005-1016.e3. PubMed ID: 28781124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
    Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
    Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS
    Bröker J; Waterson AG; Smethurst C; Kessler D; Böttcher J; Mayer M; Gmaschitz G; Phan J; Little A; Abbott JR; Sun Q; Gmachl M; Rudolph D; Arnhof H; Rumpel K; Savarese F; Gerstberger T; Mischerikow N; Treu M; Herdeis L; Wunberg T; Gollner A; Weinstabl H; Mantoulidis A; Krämer O; McConnell DB; W Fesik S
    J Med Chem; 2022 Nov; 65(21):14614-14629. PubMed ID: 36300829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition.
    Huynh MV; Parsonage D; Forshaw TE; Chirasani VR; Hobbs GA; Wu H; Lee J; Furdui CM; Poole LB; Campbell SL
    J Biol Chem; 2022 Aug; 298(8):102186. PubMed ID: 35753348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
    Molina-Arcas M; Samani A; Downward J
    Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of Noncovalent Recognition and Reactivity to the Optimization of Covalent Inhibitors: A Case Study on KRas
    Péczka N; Ranđelović I; Orgován Z; Csorba N; Egyed A; Petri L; Ábrányi-Balogh P; Gadanecz M; Perczel A; Tóvári J; Schlosser G; Takács T; Mihalovits LM; Ferenczy GG; Buday L; Keserű GM
    ACS Chem Biol; 2024 Aug; 19(8):1743-1756. PubMed ID: 38991015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity.
    Imaizumi T; Akaiwa M; Abe T; Nigawara T; Koike T; Satake Y; Watanabe K; Kaneko O; Amano Y; Mori K; Yamanaka Y; Nagashima T; Shimazaki M; Kuramoto K
    Bioorg Med Chem; 2022 Oct; 71():116949. PubMed ID: 35926326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress on Covalent Inhibition of KRAS(G12C).
    Westover KD; Jänne PA; Gray NS
    Cancer Discov; 2016 Mar; 6(3):233-4. PubMed ID: 26951837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant.
    Zhang Z; Wang X; Ye J; Liu H; Fang J; Zhang M; Li Y; Huang J; Zhang D; Wang J; Zhang X
    Mol Pharm; 2021 Sep; 18(9):3509-3518. PubMed ID: 34410132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents.
    Li L; Zhao H; Liao H; Chen J; Liu J; Chen J
    Bioorg Chem; 2021 May; 110():104825. PubMed ID: 33774492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
    Huynh MV; Campbell SL
    Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugging K-Ras
    Ni D; Li X; He X; Zhang H; Zhang J; Lu S
    Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
    Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugging all RAS isoforms with one pocket.
    Kessler D; Bergner A; Böttcher J; Fischer G; Döbel S; Hinkel M; Müllauer B; Weiss-Puxbaum A; McConnell DB
    Future Med Chem; 2020 Nov; 12(21):1911-1923. PubMed ID: 32779487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
    Roskoski R
    Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological targeting of RAS: Recent success with direct inhibitors.
    O'Bryan JP
    Pharmacol Res; 2019 Jan; 139():503-511. PubMed ID: 30366101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAS-targeted therapies: is the undruggable drugged?
    Moore AR; Rosenberg SC; McCormick F; Malek S
    Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
    Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.